Abstract:Background Disease-modifying treatments are in development for Huntington's disease; crucial to their success is to identify a timepoint in a patient's life when there is a measurable biomarker of early neurodegeneration while clinical function is still intact. We aimed to identify this timepoint in a novel cohort of young adult premanifest Huntington's disease gene carriers (preHD) far from predicted clinical symptom onset. Methods We did the Huntington's disease Young Adult Study (HD-YAS) in the UK. We recruited young adults with preHD and controls matched for age, education, and sex to ensure each group had at least 60 participants with imaging data, accounting for scan fails. Controls either had a family history of Huntington's disease but a negative genetic test, or no known family history of Huntington's disease. All participants underwent detailed neuropsychiatric and cognitive assessments, including tests from the Cambridge Neuropsychological Test Automated Battery and a battery assessing emotion, motivation, impulsivity and social cognition (EMOTICOM). Imaging (done for all participants without contraindications) included volumetric MRI, diffusion imaging, and multiparametric mapping. Biofluid markers of neuronal health were examined using blood and CSF collection. We did a cross-sectional analysis using general least-squares linear models to assess group differences and associations with age and CAG length, relating to predicted years to clinical onset. Results were corrected for multiple comparisons using the false discovery rate (FDR), with FDR <0.05 deemed a significant result. Findings Data were obtained between Aug 2, 2017, and April 25, 2019. We recruited 64 young adults with preHD and 67 controls. Mean ages of participants were 29.0 years (SD 5.6) and 29.1 years (5.7) in the preHD and control groups, respectively. We noted no significant evidence of cognitive or psychiatric impairment in preHD participants 23.6 years (SD 5.8) from predicted onset (FDR 0.22-0.87 for cognitive measures, 0.31-0.91 for neuropsychiatric measures). The preHD cohort had slightly smaller putamen volumes (FDR=0.03), but this did not appear to be closely related to predicted years to onset (FDR=0.54). There were no group differences in other brain imaging measures (FDR >0.16). CSF neurofilament light protein (NfL), plasma NfL, and CSF YKL-40 were elevated in this far-from-onset preHD cohort compared with controls (FDR<0.0001, =0.01, and =0.03, respectively). CSF NfL elevations were more likely in individuals closer to expected clinical onset (FDR <0.0001). Interpretation We report normal brain function yet a rise in sensitive measures of neurodegeneration in a preHD cohort approximately 24 years from predicted clinical onset. CSF NfL appears to be a more sensitive measure than plasma NfL to monitor disease progression. This preHD cohort is one of the earliest yet studied, and our findings could be used to inform decisions about when to initiate a potential future intervention to delay or prevent further neurodegeneration while function is intact.

Brain urea increase is an early Huntington’s disease pathogenic event observed in a prodromal transgenic sheep model and HD cases

Metabolic disruption identified in the Huntington’s disease transgenic sheep model

Dysregulation of C/EBPalpha by Mutant Huntingtin Causes the Urea Cycle Deficiency in Huntington's Disease.

Linking White Matter and Deep Gray Matter Alterations in Premanifest Huntington Disease.

Volumetric MRI-Based Biomarkers in Huntington's Disease: An Evidentiary Review

Huntington disease: natural history, biomarkers and prospects for therapeutics

Postmortem neuropathology in early Huntington disease

F05 Biological and Clinical Characteristics of Gene Carriers Far from Predicted Onset in the Hd-Yas Study: a Cross-Sectional Analysis

Imaging Glucose Metabolism and Dopaminergic Dysfunction in Sheep (Ovis aries) Brain Using Positron Emission Tomography Imaging Reveals Abnormalities in OVT73 Huntington's Disease Sheep

Extensive multiregional urea elevations in a case-control study of vascular dementia point toward a novel shared mechanism of disease amongst the age-related dementias

Longitudinal imaging highlights preferential basal ganglia circuit atrophy in Huntington's disease

Dysregulation of protein SUMOylation networks in Huntington's disease R6/2 mouse striatum

Ubiquitin: a potential cerebrospinal fluid progression marker in Huntington's disease

Huntington Disease: Linking Pathogenesis to the Development of Experimental Therapeutics

Mapping the Order and Pattern of Brain Structural MRI Changes Using Change‐point Analysis in Premanifest Huntington's Disease

Integrated multi-omics analysis of Huntington disease identifies pathways that modulate protein aggregation

Multi-OMIC analysis of Huntington disease reveals a neuroprotective astrocyte state

Huntingtons-Disease Gene - Regional and Cellular Expression in Brain of Normal and Affected Individuals

Genetic topography and cortical cell loss in Huntington's disease link development and neurodegeneration

Altered Iron and Microstructure in Huntington's Disease Subcortical Nuclei: Insight From 7T MRI